These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 22357174

  • 1. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients.
    Wadei HM, Zaky ZS, Keaveny AP, Rosser B, Jones M, Mai ML, Bulatao I, Gonwa TA.
    Transplantation; 2012 May 27; 93(10):1006-12. PubMed ID: 22357174
    [Abstract] [Full Text] [Related]

  • 2. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 3. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A.
    Transplant Proc; 2009 Oct 27; 41(8):3308-10. PubMed ID: 19857737
    [Abstract] [Full Text] [Related]

  • 4. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.
    Liver Transpl; 2003 Oct 27; 9(10):1079-85. PubMed ID: 14526403
    [Abstract] [Full Text] [Related]

  • 5. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 6. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP.
    Clin Transplant; 2009 Aug 27; 23(6):887-96. PubMed ID: 19681971
    [Abstract] [Full Text] [Related]

  • 7. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Aug 27; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 8. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug 27; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.
    Liver Transpl; 2007 May 27; 13(5):658-64. PubMed ID: 17457887
    [Abstract] [Full Text] [Related]

  • 12. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
    Sánchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E, Perez-Flores I, Gómez-Alamillo C, Fernández-Pérez C, Arias M, Barrientos A.
    Transplantation; 2012 Feb 27; 93(4):398-405. PubMed ID: 22245871
    [Abstract] [Full Text] [Related]

  • 13. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Transplant Proc; 2006 Dec 27; 38(10):3473-5. PubMed ID: 17175308
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun 27; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F, Budde K, Slowinski T, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM.
    Transpl Int; 2008 Feb 27; 21(2):152-5. PubMed ID: 18005087
    [Abstract] [Full Text] [Related]

  • 20. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Feb 27; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.